Deloitte Insights delivers proprietary research designed to help organizations turn their aspirations into action.

DELOITTE INSIGHTS

  • Home
  • Spotlight
    • Weekly Global Economic Outlook
    • Top 10 Reading Guide
    • Celebrating Earth Month
    • Artificial Intelligence
    • Resilience
  • Topics
    • Strategy
    • Economy & Society
    • Operations
    • Workforce
    • Technology
  • Industries
    • Consumer
    • Energy, Resources, & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Technology, Media, & Telecom
  • More from Deloitte Insights
    • About
    • Deloitte Insights Magazine
    • Press Room Podcasts
Deloitte.com
Deloitte Insights logo
  • SPOTLIGHT
    • Weekly Global Economic Outlook
    • Top 10 Reading Guide
    • Celebrating Earth Month
    • Resilience
    • Artificial Intelligence
  • TOPICS
    • Strategy
    • Economy & Society
    • Operations
    • Workforce
    • Technology
  • INDUSTRIES
    • Consumer
    • Energy, Resources, & Industrials
    • Financial Services
    • Government & Public Services
    • Life Sciences & Health Care
    • Technology, Media,& Telecom
  • MORE FROM DELOITTE INSIGHTS
    • About
    • Deloitte Insights Magazine
    • Press Room Podcasts
  • Welcome!

    For personalized content and settings, go to your My Deloitte Dashboard

    Latest Insights

    Creating opportunity at the intersection of climate disruption and regulatory change

    Article
     • 
    7-min read

    Better questions about generative AI

    Article
     • 
    2-min read

    Recommendations

    Tech Trends 2025

    Article

    TMT Predictions 2025

    Article

    About Deloitte Insights

    About Deloitte Insights

    Deloitte Insights Magazine, issue 33

    Magazine

    Topics for you

    • Business Strategy & Growth
    • Leadership
    • Operations
    • Marketing & Sales
    • Diversity, Equity, & Inclusion
    • Emerging Technologies
    • Economy

    Watch & Listen

    Dbriefs

    Stay informed on the issues impacting your business with Deloitte's live webcast series. Gain valuable insights and practical knowledge from our specialists while earning CPE credits.

    Deloitte Insights Podcasts

    Join host Tanya Ott as she interviews influential voices discussing the business trends and challenges that matter most to your business today. 

    Subscribe

    Deloitte Insights Newsletters

    Looking to stay on top of the latest news and trends? With MyDeloitte you'll never miss out on the information you need to lead. Simply link your email or social profile and select the newsletters and alerts that matter most to you.

Welcome back

To join via SSO please click on the key button below
Still not a member? Join My Deloitte

A new view on market access and reimbursement

by David Xie, Xiaofeng Li
  • Save for later
  • Download
  • Share
    • Share on Facebook
    • Share on Twitter
    • Share on Linkedin
    • Share by email
7 minute read 15 March 2019

A new view on market access and reimbursement Launching innovative biopharma in China

7 minute read 16 March 2019
  • David Xie China
  • Xiaofeng Li United Kingdom
  • Save for later
  • Download
  • Share
    • Share on Facebook
    • Share on Twitter
    • Share on Linkedin
    • Share by email
  • Shifting paradigm of reimbursement
  • Negotiable prices paving the way
  • Provincial nuances in reimbursement
  • Innovative programmes in the self-pay market
  • New perspectives for product launch teams
  • Conclusion

Expanding your perspective of China’s drug marketplace can open up myriad opportunities. This first in a series of four articles explores innovative alternatives in the public and self-pay markets.

In China innovative medicines have historically faced an enormous struggle to achieve reimbursement: to be included on a list of drugs for which the government will pay some of the cost.1 Any product seen as too new or too costly would likely not make it onto the list. Moreover, the list was rarely updated, meaning a lag in evaluating and accepting new medicines. But vast changes are happening in the Chinese marketplace, making it timely for biopharma companies to rethink market access and reimbursement when it comes to launching innovative medicines there; new pricing options, collaboration and creative thinking can boost your chances of success.

Shifting paradigm of reimbursement

Learn More

Explore the Launching innovative biopharma in China series

View the Life Sciences collection

Subscribe to receive more information about innovative biopharma in China

At the national level, the national reimbursement drug list (NRDL) and the essential drug list (EDL) aim to provide basic medical coverage to China’s population of 1.4 billion, typically covering well-established and relatively cheap medicines.2 Although some provinces have been able to cover additional products, overall coverage for innovative medicines has been very limited.3 Moreover, updates to the NRDL have often been significantly delayed (see Figure 1), although they should have occurred every two years – a frequency initially set by the Ministry of Health (MoH) in the early 2000s.4

After many years of delay, China updated its NRDL in early 2017 – growing the ‘Western medicine’ list by 11 per cent, to 1,297. More importantly, in addition to the updated list, a ‘to-be-negotiated’ list was published, inviting 45 medicines into price negotiations.5

Negotiable prices paving the way

The price negotiation mechanism was formally introduced at the national level for the first time in 2017, following a pilot in 2015 (see Figure 1). After a few months of negotiations, price discounts were agreed with the MoH for 36 medicines, enabling them to join the NRDL.6 The additions included expensive monoclonal antibodies drugs, established blockbuster cancer therapies and also relatively new medicines approved by the China Food and Drug Ad- ministration (CFDA). In late 2018 another 17 cancer drugs went through the same process and agreed on discounts to gain national reimbursement. Ten of those 17 drugs are medicines approved after 2017.7

China’s provinces observed the NRDL by including the products in their provincial reimbursement drug lists (PRDLs). The copayment amount for the drugs varied among provinces, meaning that patients had to pay some costs, depending on the regime adopted by each province.

Evolution of the market access landscape in China

Clearly the new pricing mechanism is an encouraging sign for domestic and multinational manufacturers of innovative medicines. But reimbursement has a drawback: an average price cut of 44 per cent across 36 products in 2017, and 57 per cent in 2018.8 Oncology products, in particular, seem to experience greater price cuts than products in other therapeutic areas, possibly due to their high cost (see Figure 2).

Provincial nuances in reimbursement

Historically, provinces in China have been able to provide better coverage for innovative medicines, de- pending on affordability and willingness to pay. They have also been more proactive in experimenting and piloting different programmes to enhance patient access (see Figure 1). Some provinces introduced the price negotiation mechanism almost three years before the national authority pilot scheme in 2015.

Certain provinces will likely continue to lead the way and introduce innovative access schemes. Zhejiang is a pioneer to watch: In early 2018, this province added another 21 drugs through the negotiation process at the provincial level. The new list includes seven drugs that did not reach an agreement in the last round of provincial negotiations, in 2014, as well as some innovative medicines newly approved by the CFDA.9

Innovative programmes in the self-pay market

Although innovative products’ inclusion in the re- imbursement system has risen significantly in China during the past 12 months, a large market remains self-pay, meaning private or out-of-pocket – patients bear the costs. This has led to many innovative access programmes in the nonpublic reimbursement space, to try to improve patient affordability (see Figure 1).

Various pharmaceutical companies participate in programmes to improve patient affordability and access to drugs; a large multinational health care company has set a precedent by heavily investing in a Shanghai innovation centre, which is due to be inaugurated in 2019.10 Moreover, starting from 2014, various manufacturers in China have tried outcome-based schemes (programmes).11 Although they focus only on the self-pay market, Deloitte’s analysis (see Figure 3) shows they share some similarities to their western counterparts: a movement toward value-based care with multiple stakeholders involved to improve patient access. Given the fast-changing health care and reimbursement landscape, it is not unreasonable to believe that outcome-based schemes with public payers may be on the horizon in China.

Similarities between innovative access programmes in China and the west

New perspectives for product launch teams

In Deloitte’s view, biopharma companies and global manufacturers of biological and chemical medicines would benefit from tailored launch campaigns to deftly handle the vastly changing Chinese marketplace. There are three aspects to consider in developing your strategy:

1. PURSUIT OF PUBLIC REIMBURSEMENT

Management and sales teams are encouraged not to assume that public reimbursement is impossible to obtain. The new price negotiation mechanism (at both the national and provincial levels) now offers possibilities to explore in terms of the drug’s price and the volumes that can be sold. Allocate internal investment to thoroughly research the options, and to evaluate the brand opportunity in a more sophisticated way than you would for a traditional volume-price assessment in a self-pay market. Practise robust scenario planning for forecast and launch activity. Finally, take a tactical approach to timing – considering, for example, that Zhejiang has updated its PRDL three times in the past three years,15 and that previously the national list was not updated from 2009 to 2016.

2. VIABILITY OF THE PUBLIC PAYER OPTION

Although the new reimbursement option is ex- citing news for the industry, it goes without saying that the public route may not be the best solution for all brands or companies. From the public payer perspective, various products differ in their reimbursement potential. For example, products with a differentiated clinical profile, large volume uptake and broad indication base tend to be favoured for inclusion. By contrast, niche-consumer–focused drugs or drugs with low-cost alternatives are much less appealing for public reimbursement.

Biopharma companies should get inside the heads of public payers. What are their immediate priorities? How do they perceive the product in terms of value? Conduct a holistic assessment of product characteristics to ensure effective engagement with payers. Then evaluate the profitability of commercial business cases carefully. In the past, there have been clear winners who exchanged price for volume, but also less successful cases where reimbursement did not help a brand achieve the performance expected.

3. CHOOSING THE MODEL, SHAPING THE MARKET

The landscape of both the private and public markets will keep evolving in China. Companies that want to succeed in launching future products must stay on top of the changing dynamics and continue to explore new access options for patients. Some innovative contracting programmes in the western market have not yet been widely applied in China, such as orphan disease-specific reimbursement, risk-sharing programmes or volume-based contracting, to name just a few. Those programmes make possible a win-win situation for customers and biopharma companies, if tailored to the Chinese market.

For the public market, as the introduction of price negotiation has shown, many new mechanisms began at the provincial and local levels, where some stakeholders may be more open to discuss innovative programmes. In the private sector, the evolving network of health care providers and private health insurance providers offers new opportunities to enhance patient access through different models of partnership and collaboration. Consider the different needs of customers/patients, and structure your offering to provide value to all the various stakeholders, aiming to shape the development of the market access system together.

Conclusion

Capitalising on opportunity in China requires a fresh and adaptable view of the evolving system. Beyond that, strong collaboration and organisational capabilities are a necessity – for example, in relation to government affairs and market access functions. Early on, define your product’s opportunities and obstacles, and use these to shape your launch model. This approach can lead beyond launch success to optimising the market access system as a whole. Explore further insights into launching innovative biopharmaceuticals in China with three other articles in this series, on: digital technologies, regulations and the changing health care environment.

Explore further insights into launching innovative biopharmaceuticals in China with three other articles in this series, on: digital technologies, regulations and the changing health care environment.

 

Acknowledgments

The authors would like to thank An Li of Monitor Deloitte for her contributions to this article.

Cover image by: Mike Ellis

Endnotes
    1. This estimation represents a compound annual growth rate of more than 5.5 per cent from 2017. Yixi Chen et al., “Drug pricing reform in China: Analysis of piloted approaches and potential impact of the reform,” Journal of Market Access & Health Policy (2016), DOI: 10.3402/jmahp.v4.30458. View in article

    2. Pacific Bridge Medical, “Market access in China: Drug listing, bidding, pricing and reimbursement,” 11 June 2014 View in article

    3. Jing Sun et al., “A review of promoting access to medicines in China - problems and recommendations,” BMC Health Services Research (2018), DOI: 10.1186/s12913-018-2875-6 View in article

    4. Jia Hu and Elias Mossialos, “Pharmaceutical pricing and reimbursement policy and its effect in China,” Chinese Journal of Health Policy 10, no. 2 (2017): pp. 5–15. View in article

    5. Hong Li et al., “Recent pricing negotiations on innovative medicines pilot in China: Experiences, implications, and suggestions,” Value in Health Regional Issues (2018): pp. 133–37, DOI: 10.1016/j.vhri.2018.01.009. View in article

    6. Yazan Saleh, “China updates NRDL with blockbuster therapies,” Decision Resource Group blog, 14 September 2017. View in article

    7. Liu Caiyu, “17 cancer drugs covered by medical insurance,” Global Times, 10 October 2018. View in article

    8. “17 kinds of anticancer drugs waist cut type price cut into the medical insurance, patients still need to break the benefits,” Sohu News, 11 October 2018. View in article

    9. Zhejiang news, “Bing Zhang, Good news! The special drugs of Zhejiang PRDL for major disease have increased to 28 drugs, and the price cut was significant,” 18 January 2018. View in article

    10. Zhejiang News, “Bing Zhang, Zhejiang will begin to add the 17 anti-cancer drugs to PRDL next month, ahead of other provinces,” 12 October 2018. View in article

    11. MediTrust Health, “Magnesium Health joins Huatai Insurance to launch the Teresa® Cost Compensation Guarantee Exclusive Program – an innovative payment model for efficacy,” 7 December 2017. View in article

    12. European Medicines Agency website. View in article

    13. Trulicity product website. View in article

    14. European Medicines Agency website. View in article

    15. Sohu News, “Zhejiang execute new PRDL on 1st September,” 23 August 2017 View in article

Show moreShow less

Topics in this article

Pharmaceutical Manufacturers​ , Center for Health Solutions

LSHC China

The LSHC team at Deloitte Consulting China supports a multitude of product launches every year. We help our clients prioritize launch assets based on a holistic assessment of external and internal attractiveness factors. Our insights into rapidly changing regulatory policies allow for clinical and regulatory affairs organizations to make informed decisions within accurate regulatory paths when bringing assets to China. We help commercial organizations to develop impactful brand strategy leveraging our industry-leading market excellence methodology and commercial innovation framework, activated by a large network of KOLs and patient organizations. We are also the leader in end-to-end market access planning, including scenario based access strategy, TA level HEOR analytics, as well design and implementation of specific access models and more innovative access contracts.

Learn more
Get in touch
Contact
  • Andrew Yu
  • Deloitte China Life Sciences & Health Care Consulting Leader, Managing partner
  • Deloitte China
  • andryu@deloitte.com.cn
  • +86 21 23166913

Download Subscribe

Related content

img Trending

Will political tensions derail economic gains in Asia Pacific?

Article 6 years ago
img Trending

Survey finds biopharma companies lag in digital transformation

Article 6 years ago
img Trending

Digital R&D: Transforming the future of clinical development

Article 7 years ago
img Trending

The future of real-world evidence

Article 6 years ago

Read other articles in the series

  • Gain the edge in a fast-moving market Article6 years ago
  • A new view on China’s digital health care Article6 years ago
David Xie

David Xie

David is a director based in Deloitte’s Shanghai office. David has extensive R&D operations and strategy consulting experience. In his consulting career, David worked with various clients from the pharmaceutical, provider, private equity and not-for-profit fields, focusing on strategy and innovation projects as well as market access and organisational transformation, private equity investments and global health delivery.

  • daxie@deloitte.com.cn
  • +862161411209
Xiaofeng Li

Xiaofeng Li

Li is a manager at Deloitte's Strategy Consulting practice and specialises in the life sciences and health care industry, focusing on commercial and clinical development as well as corporate strategy. He brings in-depth knowledge of health care systems in global markets as well as a high level of experience in delivering insights and solutions for a variety of complex strategic issues over a broad range of therapeutic areas.

  • xiaofli@deloitte.co.uk
  • +442070073042

Share article highlights

See something interesting? Simply select text and choose how to share it:

Email a customized link that shows your highlighted text.
Copy a customized link that shows your highlighted text.
Copy your highlighted text.

A new view on market access and reimbursement has been saved

A new view on market access and reimbursement has been removed

An Article Titled A new view on market access and reimbursement already exists in Saved items

Invalid special characters found 
Forgot password

To stay logged in, change your functional cookie settings.

OR

Social login not available on Microsoft Edge browser at this time.

Connect Accounts

Connect your social accounts

This is the first time you have logged in with a social network.

You have previously logged in with a different account. To link your accounts, please re-authenticate.

Log in with an existing social network:

To connect with your existing account, please enter your password:

OR

Log in with an existing site account:

To connect with your existing account, please enter your password:

Forgot password

Subscribe

to receive more business insights, analysis, and perspectives from Deloitte Insights
✓ Link copied to clipboard

Deloitte Insights delivers proprietary research designed to help organizations turn their aspirations into action.

Deloitte Insights

  • Home
  • Topics
  • Industries
  • About Deloitte Insights

Spotlight

  • Weekly Global Economic Outlook
  • Top 10 Reading Guide
  • Celebrating Earth Month
  • Artificial Intelligence
  • Resilience
Deloitte logo

Learn about Deloitte’s offerings, people, and culture as a global provider of audit, assurance, consulting, financial advisory, risk advisory, tax, and related services.

  • Terms of Use
  • Privacy
  • Privacy Shield
  • Cookies
  • Legal Information for Job Seekers
  • Labor Condition Applications
  • Do Not Sell My Personal Information